CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival

Pancreas. 2014 Apr;43(3):380-8. doi: 10.1097/MPA.0000000000000097.

Abstract

Objectives: The objectives of this study were to study the expression status of markers associated with epithelial-to-mesenchymal transition (EMT) and metastasis in pancreatic ductal adenocarcinomas (PDACs) and to explore the prognostic value of these markers.

Methods: Immunohistochemical stains for CD24, CD44, E-cadherin, N-cadherin, Snail, S100A4, Vimentin, urokinase-type plasminogen activator receptor, Ezrin, and matrix metalloproteinase 2 were performed on 67 resected PDACs.

Results: Proteins associated with EMT and metastasis were more frequently expressed in PDACs with poor differentiation, higher tumor stage, and lymphatic and perineural invasion. CD24 expression was associated with frequent expression of EMT markers (CD44 [P = 0.004], S100A4 [P < 0.001], Vimentin [P = 0.022], urokinase-type plasminogen activator receptor [P = 0.002], and Ezrin [P = 0.010]). CD24 and S100A4 expressions in PDAC were significant prognostic factors for early tumor recurrence (hazard risk [HR], 5.185 and 2.490, P = 0.048 and 0.009, respectively) and poor survival (HR, 11.977 and 3.202, P = 0.006 and 0.004, respectively). In addition, the interaction between CD24 and S100A4 expression status was a significant prognostic factor for poor survival (HR, 18.518, P = 0.003).

Conclusions: The expression of markers of EMT and metastasis in PDACs was significantly associated with pathologic features of aggressiveness. CD24 and S100A4 expressions were significant predictors of poor survival; thus, immunohistochemistry for these markers in resected specimens may help to identify PDAC patients with a poor prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / surgery
  • Aged
  • Biomarkers, Tumor / biosynthesis*
  • CD24 Antigen / biosynthesis*
  • Carcinoma, Pancreatic Ductal / metabolism*
  • Carcinoma, Pancreatic Ductal / pathology
  • Carcinoma, Pancreatic Ductal / surgery
  • Cytoskeletal Proteins / biosynthesis
  • Epithelial-Mesenchymal Transition
  • Female
  • Humans
  • Hyaluronan Receptors / biosynthesis
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Outcome Assessment, Health Care / statistics & numerical data
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery
  • Prognosis
  • Proportional Hazards Models
  • Receptors, Urokinase Plasminogen Activator / biosynthesis
  • S100 Calcium-Binding Protein A4
  • S100 Proteins / biosynthesis*
  • Vimentin / biosynthesis

Substances

  • Biomarkers, Tumor
  • CD24 Antigen
  • Cytoskeletal Proteins
  • Hyaluronan Receptors
  • Receptors, Urokinase Plasminogen Activator
  • S100 Calcium-Binding Protein A4
  • S100 Proteins
  • Vimentin
  • ezrin
  • S100A4 protein, human